3Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004, 363: 2022-2031.
4Hasford J, Mimran A, Simons WR. A population-based european cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens, 2002, 16: 569-575.
5Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther, 1998, 20: 671-681.
6Elliott WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens, 2001, S291-S295.
7Shimada K, Kawamoto A, Matsubayashi K, et al. Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens, 1992, 10: 875-878.
8Lacourciere Y, Lenis J, R Orchard, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit, 1998, 3: 295-302.
9Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA, 2003, 289: 2560-2571.
10MacKay JH, Arcuri KE, Goldberg A. I, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med, 1996, 156: 278-285.
5Dronavalli S,Duka I,Bakris G L.The pathogenesis of diabetic nephropathy.Nat Clin Pract Endocrinol Metab,2008,4(8):444-452.
6Mogensen C E,Christensen C K,Vittinghus E.The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy.Diabetes, 1983,32(Suppl 2):64-78.
